Australia is eagerly anticipating the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist , representing a significant advance in obesity treatment . Early clinical trials have demonstrated https://giantbikesusa559182.jasperwiki.com/8085506/emerging_medication_in_australia_a_promising_solution_for_obesity_management